

Psychopharmacology

BULLETIN

ORIGINAL PRESENTATIONS

- 8 **Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder**
Brianna Brown, Larry Alphs, Ibrahim Turkoz, Yong Yue
- 17 **Correlation of Caregiver Burden and Baseline Characteristics of Caregivers and Patients in Their Care with Recent-Onset Psychosis: The FIRST Study**
Branislav Mancevski, Jagadish Gogate, Katie Ashcroft, Kristy Tardieu, Ed Kim
- 26 **A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil**
Robert Risinger, Marjie Hard, Peter J. Weiden
- 35 **Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil**
Henry A. Nasrallah, Ralph Aquila, Arielle D. Stanford, Hasan H. Jamal, Peter J. Weiden, Robert Risinger
- 44 **Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects**
Rosa Luo, Haig Bozigian, Roland Jimenez, Gordon Loewen, Christopher F. O'Brien
- 53 **Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder**
Christoph U. Correll, Richard C. Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O'Brien
- 61 **Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder**
Richard C. Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O'Brien
- 69 **Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder**
John M. Kane, Christoph U. Correll, Grace S. Liang, Joshua Burke, Christopher F. O'Brien

CLINICAL EDUCATIONAL REVIEW

- 77 **Reference Guide**
Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia